JP2020509031A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020509031A5 JP2020509031A5 JP2019547310A JP2019547310A JP2020509031A5 JP 2020509031 A5 JP2020509031 A5 JP 2020509031A5 JP 2019547310 A JP2019547310 A JP 2019547310A JP 2019547310 A JP2019547310 A JP 2019547310A JP 2020509031 A5 JP2020509031 A5 JP 2020509031A5
- Authority
- JP
- Japan
- Prior art keywords
- preparation according
- monoclonal antibody
- seq
- concentration
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009472 formulation Methods 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims 12
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 8
- 239000000872 buffer Substances 0.000 claims 5
- 229960002885 histidine Drugs 0.000 claims 5
- 235000000346 sugar Nutrition 0.000 claims 5
- 239000004094 surface-active agent Substances 0.000 claims 5
- 241000725643 Respiratory syncytial virus Species 0.000 claims 4
- CMXXUDSWGMGYLZ-XRIGFGBMSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride;hydrate Chemical compound O.Cl.OC(=O)[C@@H](N)CC1=CN=CN1 CMXXUDSWGMGYLZ-XRIGFGBMSA-N 0.000 claims 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical group OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 3
- 229960003589 arginine hydrochloride Drugs 0.000 claims 3
- 229920000136 polysorbate Polymers 0.000 claims 3
- 229950008882 polysorbate Drugs 0.000 claims 3
- 150000003839 salts Chemical group 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 230000003097 anti-respiratory effect Effects 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 229920005862 polyol Polymers 0.000 claims 1
- 150000003077 polyols Chemical class 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022045862A JP7446356B2 (ja) | 2017-03-01 | 2022-03-22 | 抗ｒｓｖモノクローナル抗体製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762465379P | 2017-03-01 | 2017-03-01 | |
| US62/465,379 | 2017-03-01 | ||
| PCT/US2018/020264 WO2018160722A1 (en) | 2017-03-01 | 2018-02-28 | Anti-rsv monoclonal antibody formulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022045862A Division JP7446356B2 (ja) | 2017-03-01 | 2022-03-22 | 抗ｒｓｖモノクローナル抗体製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020509031A JP2020509031A (ja) | 2020-03-26 |
| JP2020509031A5 true JP2020509031A5 (enExample) | 2021-03-04 |
| JP7046088B2 JP7046088B2 (ja) | 2022-04-01 |
Family
ID=61903153
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547310A Active JP7046088B2 (ja) | 2017-03-01 | 2018-02-28 | 抗ｒｓｖモノクローナル抗体製剤 |
| JP2022045862A Active JP7446356B2 (ja) | 2017-03-01 | 2022-03-22 | 抗ｒｓｖモノクローナル抗体製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022045862A Active JP7446356B2 (ja) | 2017-03-01 | 2022-03-22 | 抗ｒｓｖモノクローナル抗体製剤 |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US10774133B2 (enExample) |
| EP (1) | EP3589648A4 (enExample) |
| JP (2) | JP7046088B2 (enExample) |
| KR (2) | KR102668158B1 (enExample) |
| CN (3) | CN116059343A (enExample) |
| AR (1) | AR111083A1 (enExample) |
| AU (2) | AU2018227502B2 (enExample) |
| BR (1) | BR112019017755A2 (enExample) |
| CA (1) | CA3051864A1 (enExample) |
| CL (1) | CL2019002478A1 (enExample) |
| CO (1) | CO2019009034A2 (enExample) |
| CR (1) | CR20190400A (enExample) |
| EA (1) | EA201991701A1 (enExample) |
| EC (1) | ECSP19062769A (enExample) |
| GB (1) | GB2564175B (enExample) |
| IL (2) | IL312499A (enExample) |
| MX (1) | MX2019010408A (enExample) |
| MY (1) | MY206022A (enExample) |
| PH (1) | PH12019501979A1 (enExample) |
| SG (1) | SG11201906853QA (enExample) |
| TW (2) | TW202228779A (enExample) |
| UA (1) | UA128450C2 (enExample) |
| WO (1) | WO2018160722A1 (enExample) |
| ZA (1) | ZA202006797B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3094353T1 (sl) | 2014-01-15 | 2020-07-31 | Medimmune, Llc | RSY-specifična protitelesa in njihovi funkcionalni deli |
| EP4606820A3 (en) * | 2015-11-30 | 2025-10-29 | Medimmune, LLC | Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
| TW202228779A (zh) * | 2017-03-01 | 2022-08-01 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
| EP3589318A1 (en) * | 2017-03-01 | 2020-01-08 | MedImmune Limited | Formulations of monoclonal antibodies |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| SG11201909955XA (en) | 2017-05-02 | 2019-11-28 | Merck Sharp & Dohme | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
| MY209127A (en) * | 2018-10-18 | 2025-06-23 | Merck Sharp & Dohme Llc | Formulations of anti-rsv antibodies and methods of use thereof |
| EP3876990A4 (en) | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
| MX2021009851A (es) | 2019-02-18 | 2021-09-10 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos. |
| CN113993884A (zh) * | 2019-04-18 | 2022-01-28 | 弗劳恩霍夫应用研究促进协会 | 抑制呼吸道合胞病毒感染的生物及合成分子 |
| US12024553B2 (en) * | 2019-04-30 | 2024-07-02 | Medimmune Limited | Dosage regimens for and compositions including anti-RSV antibodies |
| TWI896628B (zh) | 2020-03-26 | 2025-09-11 | 美國凡德貝爾大學 | 針對嚴重急性呼吸症候群冠狀病毒２(SARS-CoV-2)之人單株抗體 |
| WO2022026914A1 (en) * | 2020-07-31 | 2022-02-03 | Alamab Therapeutics, Inc. | Anti-connexin antibody formulations |
| CN115960214A (zh) * | 2021-10-12 | 2023-04-14 | 中国科学院分子细胞科学卓越创新中心 | 中和呼吸道合胞病毒的全人抗体的设计及应用 |
| TW202342510A (zh) | 2022-02-18 | 2023-11-01 | 英商Ｒｑ生物科技有限公司 | 抗體 |
| CN116987183B (zh) * | 2022-07-22 | 2024-10-15 | 北京智仁美博生物科技有限公司 | 抗呼吸道合胞病毒中和性抗体及其用途 |
| WO2024120516A1 (zh) * | 2022-12-08 | 2024-06-13 | 南京诺唯赞生物科技股份有限公司 | 特异性结合rsv的抗体 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| WO1997010846A1 (en) | 1995-09-18 | 1997-03-27 | Intracel Corporation | Neutralizing monoclonal antibodies to respiratory syncytial virus |
| GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| US20030138417A1 (en) * | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| US7425618B2 (en) * | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| AU2013201261B2 (en) | 2002-06-14 | 2016-06-23 | Medimmune, Llc | Stabilized liquid anti-RSV antibody formulations |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| DK1610820T4 (da) * | 2003-04-04 | 2013-11-04 | Genentech Inc | Høj-koncentration antistof- og proteinformuleringer |
| TW200636064A (en) | 2004-10-28 | 2006-10-16 | Centocor Inc | Anti-respiratory syncytial virus antibodies, antigens and uses thereof |
| WO2007103470A2 (en) * | 2006-03-06 | 2007-09-13 | Medimmune, Inc. | Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| RU2011122615A (ru) | 2008-11-05 | 2012-12-20 | Мерк Шарп Энд Домэ Корп. | Живой аттенуированный респираторно-синцитиальный вирус |
| WO2011017070A1 (en) * | 2009-07-28 | 2011-02-10 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| CA2776249C (en) | 2009-10-06 | 2021-01-19 | Medimmune Ltd | Rsv-specific binding molecule |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| CL2011003002A1 (es) | 2011-11-25 | 2012-05-25 | Univ Pontificia Catolica Chile | Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento. |
| CA3204402A1 (en) * | 2012-03-26 | 2013-10-03 | Sanofi | Stable anti-cxcr5 igg4 antibody formulations |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| DK2950886T3 (da) | 2013-02-01 | 2020-03-23 | Medimmune Llc | Respiratorisk syncytialvirus-f-protein-epitoper |
| SI3094353T1 (sl) | 2014-01-15 | 2020-07-31 | Medimmune, Llc | RSY-specifična protitelesa in njihovi funkcionalni deli |
| AU2015332151A1 (en) * | 2014-10-18 | 2017-04-27 | Pfizer Inc. | Anti-IL-7R antibody compositions |
| EA039065B1 (ru) * | 2015-07-07 | 2021-11-29 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцина против rsv |
| JO3555B1 (ar) | 2015-10-29 | 2020-07-05 | Merck Sharp & Dohme | جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري |
| TW202228779A (zh) * | 2017-03-01 | 2022-08-01 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
| EP3589318A1 (en) * | 2017-03-01 | 2020-01-08 | MedImmune Limited | Formulations of monoclonal antibodies |
| US12024553B2 (en) * | 2019-04-30 | 2024-07-02 | Medimmune Limited | Dosage regimens for and compositions including anti-RSV antibodies |
-
2018
- 2018-02-13 TW TW111113045A patent/TW202228779A/zh unknown
- 2018-02-13 TW TW107105368A patent/TWI761453B/zh active
- 2018-02-23 GB GB1802974.4A patent/GB2564175B/en active Active
- 2018-02-26 AR ARP180100448A patent/AR111083A1/es not_active Application Discontinuation
- 2018-02-28 EP EP18761614.9A patent/EP3589648A4/en active Pending
- 2018-02-28 BR BR112019017755A patent/BR112019017755A2/pt not_active Application Discontinuation
- 2018-02-28 CA CA3051864A patent/CA3051864A1/en active Pending
- 2018-02-28 WO PCT/US2018/020264 patent/WO2018160722A1/en not_active Ceased
- 2018-02-28 CR CR20190400A patent/CR20190400A/es unknown
- 2018-02-28 IL IL312499A patent/IL312499A/en unknown
- 2018-02-28 UA UAA201908966A patent/UA128450C2/uk unknown
- 2018-02-28 MX MX2019010408A patent/MX2019010408A/es unknown
- 2018-02-28 EA EA201991701A patent/EA201991701A1/ru unknown
- 2018-02-28 AU AU2018227502A patent/AU2018227502B2/en active Active
- 2018-02-28 US US15/907,876 patent/US10774133B2/en active Active
- 2018-02-28 KR KR1020227003517A patent/KR102668158B1/ko active Active
- 2018-02-28 CN CN202210988780.XA patent/CN116059343A/zh active Pending
- 2018-02-28 CN CN202410036839.4A patent/CN117982637A/zh active Pending
- 2018-02-28 KR KR1020197025250A patent/KR102359181B1/ko active Active
- 2018-02-28 CN CN201880014929.6A patent/CN110418803B/zh active Active
- 2018-02-28 MY MYPI2019004962A patent/MY206022A/en unknown
- 2018-02-28 SG SG11201906853QA patent/SG11201906853QA/en unknown
- 2018-02-28 JP JP2019547310A patent/JP7046088B2/ja active Active
- 2018-02-28 IL IL268202A patent/IL268202B2/en unknown
-
2019
- 2019-08-21 CO CONC2019/0009034A patent/CO2019009034A2/es unknown
- 2019-08-28 CL CL2019002478A patent/CL2019002478A1/es unknown
- 2019-08-29 EC ECSENADI201962769A patent/ECSP19062769A/es unknown
- 2019-08-29 PH PH12019501979A patent/PH12019501979A1/en unknown
-
2020
- 2020-07-13 US US16/927,169 patent/US11667698B2/en active Active
- 2020-10-30 ZA ZA2020/06797A patent/ZA202006797B/en unknown
-
2021
- 2021-06-18 US US17/351,348 patent/US11286294B2/en active Active
-
2022
- 2022-03-22 JP JP2022045862A patent/JP7446356B2/ja active Active
- 2022-11-04 AU AU2022263564A patent/AU2022263564B2/en active Active
-
2023
- 2023-04-28 US US18/309,475 patent/US20230399383A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020509031A5 (enExample) | ||
| JP2024016177A5 (enExample) | ||
| US20240182573A1 (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| JP2020518599A5 (enExample) | ||
| JP2020518600A5 (enExample) | ||
| JP6647208B2 (ja) | 抗ｉｌ−１７抗体、その生産および使用のための方法 | |
| TWI761453B (zh) | 抗rsv單株抗體配製物 | |
| JP2022079549A5 (enExample) | ||
| CN111971062A (zh) | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 | |
| JP2023109942A5 (enExample) | ||
| JP2020518598A5 (enExample) | ||
| CN114616249A (zh) | 含有抗pd-l1抗体的稳定制剂 | |
| JP2018188437A5 (enExample) | ||
| JP2018535650A5 (enExample) | ||
| FI4045533T3 (fi) | Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2) | |
| JP2019163319A5 (enExample) | ||
| JP2019031565A5 (enExample) | ||
| JP2017160208A5 (enExample) | ||
| HRP20201345T1 (hr) | Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba | |
| JP2018505177A5 (enExample) | ||
| JP2025032102A5 (enExample) | ||
| JP2020511947A5 (enExample) | ||
| KR20160079890A (ko) | 항체-약물 접합체 동결건조 제제 | |
| JP2016534052A5 (enExample) | ||
| HK1199463A1 (en) | Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile |